Skip to main content

Catalyst Calendar

Scope

Wed, Sep 30, 2026

1 updates
EPRX
8:00 AM

Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

The highest dose group of EP-104GI (Cohort 9) demonstrated durability of symptom responses out to 52 weeks, with 66% of patients (2 of 3) maintaining clinical remission 1 The second highest dose group of EP-104GI (Cohort 8b) continued to show meaningful histologic reduction in inflammation and

Trial Results • Phase 1Results event Wed, Sep 30, 2026eupraxiapharma.com

Tue, Sep 8, 2026

1 updates

Thu, Aug 13, 2026

1 updates
EPRX
8:00 AM

Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients

The number of patients experiencing moderate to severe odynophagia (pain swallowing) in the cohorts analyzed (Cohorts 7-9) was reduced from 62% at baseline to 25% from 24 through to 52 weeks post treatment In the same analysis, 23% of patients reported severe odynophagia at baseline; and no

Interim Data • Phase 1/2Interim data Thu, Aug 13, 2026eupraxiapharma.com

Tue, Aug 11, 2026

1 updates
EPRX
5:22 PM

Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results

New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI Strengthened executive team and board to bolster late-stage drug development and global commercialization capabilities.

Presentation / Abstract • Phase 1/2DDW presentation Tue, May 5, 2026eupraxiapharma.com

Mon, Jul 13, 2026

1 updates